GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heidelberg Pharma AG (LTS:0QW5) » Definitions » Earnings per Share (Diluted)

Heidelberg Pharma AG (LTS:0QW5) Earnings per Share (Diluted) : €-0.45 (TTM As of Feb. 2025)


View and export this data going back to 2011. Start your Free Trial

What is Heidelberg Pharma AG Earnings per Share (Diluted)?

Heidelberg Pharma AG's Earnings per Share (Diluted) for the three months ended in Feb. 2025 was €-0.13. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2025 was €-0.45.

Heidelberg Pharma AG's EPS (Basic) for the three months ended in Feb. 2025 was €-0.13. Its EPS (Basic) for the trailing twelve months (TTM) ended in Feb. 2025 was €-0.45.

Heidelberg Pharma AG's EPS without NRI for the three months ended in Feb. 2025 was €-0.13. Its EPS without NRI for the trailing twelve months (TTM) ended in Feb. 2025 was €-0.45.


Heidelberg Pharma AG Earnings per Share (Diluted) Historical Data

The historical data trend for Heidelberg Pharma AG's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heidelberg Pharma AG Earnings per Share (Diluted) Chart

Heidelberg Pharma AG Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.61 -0.80 -0.53 -0.44 -0.42

Heidelberg Pharma AG Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.09 -0.12 -0.11 -0.13

Competitive Comparison of Heidelberg Pharma AG's Earnings per Share (Diluted)

For the Biotechnology subindustry, Heidelberg Pharma AG's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Heidelberg Pharma AG's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's PE Ratio distribution charts can be found below:

* The bar in red indicates where Heidelberg Pharma AG's PE Ratio falls into.


;
;

Heidelberg Pharma AG Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Heidelberg Pharma AG's Earnings Per Share (Diluted) for the fiscal year that ended in Nov. 2024 is calculated as

Diluted Earnings Per Share (A: Nov. 2024 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-19.382-0)/46.605
=-0.42

Heidelberg Pharma AG's Earnings Per Share (Diluted) for the quarter that ended in Feb. 2025 is calculated as

Diluted Earnings Per Share (Q: Feb. 2025 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-5.938-0)/45.675
=-0.13

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Heidelberg Pharma AG  (LTS:0QW5) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Heidelberg Pharma AG Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Heidelberg Pharma AG's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Heidelberg Pharma AG Business Description

Traded in Other Exchanges
Address
Gregor-Mendel-Street 22, Ladenburg, DEU, 68526
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.

Heidelberg Pharma AG Headlines

No Headlines